Objective To investigate the efficacy and safety of ginkgo biloba combined with oxiracetam in patients with vascular cognitive impairment no dementia (VCIND). Methods 102 patients with VCIND were enrolled in our hospital (October 2016-June 2018). The random number table method was used to divide them into control group (n=51) and study group (n=51). On the basis of routine intervention, oxiracetam was taken in the control group for two weeks, and the research group was given Ginkgo biloba leaves on the basis of the control group for 3 months. Serum glycosylation end product receptor soluble fragment (sRAGE), β-site APP-cleaving enzyme 1 (BACE1) level, daily living ability (ADL), menory function (WMSscore)cognitive function (MoCA) and mental status (MMSE) scores, regional cerebral blood flow, adverse reactions (vomiting nausea, dizziness, rash) were compared. Results In terms of clinical efficacy, the total effective rate of the study group (94.12%) was higher than that of the control group (80.39%) (P<0.05). After the course of treatment, the serum sRAGE of the two groups was higher than that before treatment, and the level of BACE1 was lower than that before treatment. The sRAGE of the study group was higher than that of the control group, and BACE1 was lower than that of the control group. After the course of treatment, the scores of ADL, WMS, MoCA and MMSE in the two groups were higher than those before treatment, and the regional cerebral blood flow in the study group was higher than that before treatment, and the regional cerebral blood flow in the study group was higher than that in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the study group (11.76%) and the control group (7.84%). Conclusion The combination of oxiracetam and ginkgo leaves for the treatment of VCIND can effectively regulate serum sRAGE and BACE1 levels, improve cognitive function, memory function and mental state, restore daily living ability, increase regional cerebral blood flow, and improve disease overall treatment.

Objective To observe the efficacy of duloxetine combined with Flurbiprofen Cataplasms in the treatment of nonspecific costochondritis. Methods One hundred and twenty patients with nonspecific costal chondritis were selected and divided into group A and group B equally, which is 60 patients in each. Group A was combined with duloxetine and Flurbiprofen cataplasms, while group B was treated with Flurbiprofen cataplasms only. Before treatment and on 1, 3, 7 days after treatment, visual analogue scale (VAS) was used to score the pain degree of the two groups of patients by a professional physician in the double-blind condition, and evaluated the efficacy of two groups 7 days after treatment. Results After treatment 1, 3, and 7 days, the VAS scores of two groups were significantly different from those before treatment in groups (P<0.05). After treatment, 40 cases (66.7%) of patients in group A were cured, 8 cases (20%) were markedly improved, and 2 cases (3.3%) were improved. The cure rate was significantly higher than that in group B, and the differences were statistically significant (P<0.05). Conclusion Duloxetine combined with Flurbiprofen cataplasms can relieve pain symptoms of patients with non-specific costochondritis quickly, and the short-term cure rate is high.